Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.
2 reports, 2 independent
Updated Sep 25
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Moderna and Novavax partnered with Merck KGaA on an individualized neoantigen program, driven by positive Phase 2b melanoma data.Sub-event
Update on the personalized cancer vaccine collaboration between Moderna and Merck KGaA.1 source
Keep exploring
Part of
Moderna and Merck personalized cancer vaccine advancementAlso in this story
- Moderna combined its vaccine with Merck's Keytruda drug.
- Moderna, Merck, and Georgetown Lombardi Comprehensive Cancer Center are collaborating on developing a personalized cancer vaccine combination.
- Moderna and Merck developed personalized mRNA cancer vaccine Intismeran following trial success, leading to a surge in Moderna's shares.
- Moderna and Merck developed a new therapy.
The entities involved
-
Moderna
American biotechnology company
-
Merck KGaA
German multinational science and technology company
Related events
- Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.
- The European Medicines Agency is reviewing mRNA vaccine trials reported by Moderna and MSD.